MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
MiNK Therapeutics has initiated dosing of the first patient in its randomized Phase 2 clinical trial of agenT-797, an off-the-shelf iNKT cell therapy, for patients with acute lung injury and critical illness meeting Global ARDS criteria. The trial, conducted in Ukraine with plans for US site expansion, aims to evaluate clinically meaningful ICU out…